A Phase Ib, Open-Label, Single Arm Study to Assess the Safety, Pharmacokinetics, and Impact on Humoral Sensitization of SANGUINATE Infusion in Patients With End-Stage Renal Disease (ESRD)

Trial Profile

A Phase Ib, Open-Label, Single Arm Study to Assess the Safety, Pharmacokinetics, and Impact on Humoral Sensitization of SANGUINATE Infusion in Patients With End-Stage Renal Disease (ESRD)

Discontinued
Phase of Trial: Phase I

Latest Information Update: 03 May 2017

At a glance

  • Drugs PEG-haemoglobin carbon monoxide (Primary)
  • Indications Renal failure
  • Focus Adverse reactions
  • Sponsors Prolong Pharmaceuticals
  • Most Recent Events

    • 03 May 2017 Results assessing safety,pharmacokinetics and impact on humoral sensitization of SANGUINATE infusion presented at the 2017 American Transplant Congress.
    • 03 May 2017 Status changed from recruiting to discontinued according to the results published at the 2017 American Transplant Congress.
    • 15 Apr 2016 Planned End Date changed from 1 Feb 2016 to 1 Jul 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top